The Conundrum of Genetic “Drivers” in Benign Conditions
暂无分享,去创建一个
[1] Kimberly J. Johnson,et al. Neurofibromatosis type 1 , 2017, Nature Reviews Disease Primers.
[2] D. Bennett. Genetics of melanoma progression: the rise and fall of cell senescence , 2016, Pigment cell & melanoma research.
[3] J. Cuzick,et al. Abstract P3-07-02: Prognostic and predictive relevance of HER2 status in ductal carcinomain situ: Results from the UK/ANZ DCIS trial , 2016 .
[4] Jennifer Beane,et al. The Case for a Pre-Cancer Genome Atlas (PCGA) , 2016, Cancer Prevention Research.
[5] Edward S. Kim,et al. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. , 2016, JAMA oncology.
[6] J. Grandis,et al. Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection. , 2016, JAMA oncology.
[7] R. Young,et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation , 2016, Science.
[8] Avrum Spira,et al. Transforming Cancer Prevention through Precision Medicine and Immune-oncology , 2016, Cancer Prevention Research.
[9] R. Dummer,et al. The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.
[10] Siân Jones,et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA , 2015, Nature Communications.
[11] Razelle Kurzrock,et al. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.
[12] Zhenran Wang,et al. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer , 2015, Scientific Reports.
[13] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[14] D. Deming,et al. Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence , 2015, Cancer Prevention Research.
[15] R. Kurzrock,et al. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications , 2015, Cancer and Metastasis Reviews.
[16] S. Ariyan,et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.
[17] S. Berger,et al. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma. , 2015, Cancer discovery.
[18] R. Wolfe,et al. The role of BRAF mutations in primary melanoma growth rate and survival , 2015, The British journal of dermatology.
[19] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Stratton,et al. High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.
[21] R. Kurzrock,et al. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics , 2015, Cell cycle.
[22] N. Bundred,et al. Molecular phenotypes of DCIS predict overall and invasive recurrence. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] S. Kesari,et al. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer , 2015, Cell cycle.
[24] N. Ratner,et al. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor , 2015, Nature Reviews Cancer.
[25] M. Greene,et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes , 2015, British Journal of Cancer.
[26] S. Millis,et al. HER2 expression status in diverse cancers: review of results from 37,992 patients , 2015, Cancer and Metastasis Reviews.
[27] S. Kesari,et al. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics , 2015, Cell cycle.
[28] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[29] David A. Williams,et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy , 2015, Nature Genetics.
[30] J. Malvehy,et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom , 2014, Hereditary cancer in clinical practice.
[31] David R. Riley,et al. Notch1 Mutations Are Drivers of Oral Tumorigenesis , 2014, Cancer Prevention Research.
[32] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[33] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[34] O. Maertens,et al. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. , 2014, Cancer discovery.
[35] R. Kurzrock,et al. HER2 aberrations in cancer: implications for therapy. , 2014, Cancer treatment reviews.
[36] D. Peeper,et al. Near‐genomewide RNAi screening for regulators of BRAFV600E‐induced senescence identifies RASEF, a gene epigenetically silenced in melanoma , 2014, Pigment cell & melanoma research.
[37] M. Saroufim,et al. BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter? , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[38] B. Taylor,et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.
[39] X. Su,et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. , 2014, The Journal of investigative dermatology.
[40] A. Yousef,et al. Incidence of bcr‑abl fusion transcripts in healthy individuals. , 2014, Molecular medicine reports.
[41] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[42] D. Esposito,et al. Dragging ras back in the ring. , 2014, Cancer cell.
[43] Karen H. Vousden,et al. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.
[44] M. Pellegrini,et al. Molecular Profiling of Premalignant Lesions in Lung Squamous Cell Carcinomas Identifies Mechanisms Involved in Stepwise Carcinogenesis , 2014, Cancer Prevention Research.
[45] Channing J Der,et al. KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.
[46] L. Guerra,et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. , 2014, Journal of the National Cancer Institute.
[47] Razelle Kurzrock,et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. , 2014, Cell reports.
[48] Steven J. M. Jones,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[49] N. M. Powell,et al. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity , 2014, Oncotarget.
[50] R. Kurzrock,et al. NF2/Merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations , 2013, Oncotarget.
[51] Jeffrey A. Engelman,et al. Tyrosine kinase gene rearrangements in epithelial malignancies , 2013, Nature Reviews Cancer.
[52] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[53] R. Palmer,et al. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.
[54] Francisco Cervantes,et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.
[55] P. Hwu,et al. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] P. Tschandl,et al. NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi , 2013, PloS one.
[57] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[58] I. Yeh,et al. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. , 2013, Journal of the National Cancer Institute.
[59] Matthew D. Shirley,et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. , 2013, The New England journal of medicine.
[60] R. Sullivan,et al. MAP kinase signaling and inhibition in melanoma , 2013, Oncogene.
[61] J. Lee,et al. P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy , 2013, Oncotarget.
[62] Philip R. Cohen,et al. Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib. , 2013, The Journal of clinical and aesthetic dermatology.
[63] G. Millington. Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949–54) , 2013, Clinical and experimental dermatology.
[64] L. Thomas,et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants , 2013, Journal of Medical Genetics.
[65] A. Tsao,et al. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[66] G. Page,et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. , 2013, The Journal of clinical investigation.
[67] Y. Iwamoto,et al. Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors , 2012, Clinical Cancer Research.
[68] H. Haenssle,et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. , 2012, Archives of dermatology.
[69] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[70] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[71] K. Flaherty,et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[72] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[73] A. Hauschild,et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Julie C. Sapp,et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA , 2012, Nature Genetics.
[75] S. Gabriel,et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly , 2012, Nature Genetics.
[76] M. Brown,et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.
[77] H. Horlings,et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. , 2012, Genes & development.
[78] K. Flaherty,et al. From genes to drugs: targeted strategies for melanoma , 2012, Nature Reviews Cancer.
[79] I. Ahmad,et al. Mechanisms of FGFR-mediated carcinogenesis. , 2012, Biochimica et biophysica acta.
[80] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[82] E. Rakovitch,et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ , 2012, British Journal of Cancer.
[83] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[84] Arnold Munnich,et al. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model. , 2012, Human molecular genetics.
[85] J. Slopis,et al. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] John V Heymach,et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.
[87] Jordi Rodon,et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] David Haussler,et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma , 2011, Proceedings of the National Academy of Sciences.
[89] K. Gripp,et al. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations , 2011, Genetics in Medicine.
[90] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[91] Gerald C. Chu,et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. , 2011, Cancer cell.
[92] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[93] M. Hashizume,et al. The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis , 2011, Arthritis.
[94] P. Rosenberg,et al. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.
[95] E. Grande,et al. Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment , 2011, Molecular Cancer Therapeutics.
[96] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[98] J. Campisi. Cellular senescence: putting the paradoxes in perspective. , 2011, Current opinion in genetics & development.
[99] J. O'Brien,et al. Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.
[100] N. Malats,et al. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors , 2010, Proceedings of the National Academy of Sciences.
[101] Marc Ladanyi,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.
[102] J. Barrett,et al. PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.
[103] M. Landthaler,et al. Activation of the PI3K/AKT signalling pathway in non‐melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations , 2010, Experimental dermatology.
[104] M. Landthaler,et al. FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. , 2010, Experimental cell research.
[105] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[106] A. Gemma,et al. F1000 highlights , 2010 .
[107] S. Haferkamp,et al. IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence , 2010, Cell.
[108] Adam M. Gustafson,et al. Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development , 2010, Science Translational Medicine.
[109] J. Becker,et al. Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma. , 2010, The Journal of investigative dermatology.
[110] R. Kane,et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. , 2010, Journal of the National Cancer Institute.
[111] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[112] Tom Royce,et al. A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.
[113] D. Evans,et al. Orphanet Journal of Rare Diseases BioMed Central , 2009 .
[114] K. Rauen,et al. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.
[115] Y. Kubo,et al. Activation of fibroblast growth factor receptor 3 and oncogene‐induced senescence in skin tumours , 2009, The British journal of dermatology.
[116] K. Flaherty,et al. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. , 2009, Cancer research.
[117] M. Stratton,et al. The cancer genome , 2009, Nature.
[118] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[119] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[120] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[121] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[122] J. Kremer,et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.
[123] S. Jones,et al. Many roads lead to oncogene-induced senescence , 2008, Oncogene.
[124] C. Petti,et al. In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation , 2008, Modern Pathology.
[125] D. Peeper,et al. Cellular senescence in vivo: a barrier to tumorigenesis. , 2008, Current opinion in cell biology.
[126] Michael R. Green,et al. Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.
[127] R. Wellenreuther,et al. Differential gene expression in melanocytic nevi with the V600E BRAF mutation , 2007, Genes, chromosomes & cancer.
[128] M. Gambello,et al. Mortality in achondroplasia study: A 42‐year follow‐up , 2007, American journal of medical genetics. Part A.
[129] F. Real,et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern , 2007, Proceedings of the National Academy of Sciences.
[130] M. Landthaler,et al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization , 2007, Modern Pathology.
[131] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[132] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[133] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[134] K. Sims,et al. Mutational spectrum of the NF2 gene: a meta‐analysis of 12 years of research and diagnostic laboratory findings , 2007, Human mutation.
[135] M. Landthaler,et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. , 2006, The Journal of investigative dermatology.
[136] S. Puig,et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents , 2006, Journal of Medical Genetics.
[137] R. Marais,et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.
[138] N. Malats,et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] Stephen B Gruber,et al. BRAF and NRAS mutations in melanoma and melanocytic nevi , 2006, Melanoma research.
[140] Michael Landthaler,et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. , 2006, The Journal of clinical investigation.
[141] A. Hauschild,et al. Melanoma risk in congenital melanocytic naevi: a systematic review , 2006, The British journal of dermatology.
[142] D. Pinkel,et al. PI3-kinase subunits are infrequent somatic targets in melanoma. , 2006, The Journal of investigative dermatology.
[143] H. Varmus,et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.
[144] G. Shapiro,et al. Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[145] J. Hansson,et al. Mutations of PIK3CA are rare in cutaneous melanoma , 2006, Melanoma research.
[146] B. Park,et al. Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.
[147] Yiling Lu,et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.
[148] J. Minna,et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.
[149] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[150] A. Trumpp,et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. , 2005, Cancer research.
[151] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[152] S. Jhanwar,et al. The NF2 Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression , 2005, Molecular and Cellular Biology.
[153] L. Zon,et al. BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.
[154] M. Washington,et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[155] L. Koniaris,et al. Inflammatory myofibroblastic tumors , 2004, Annals of Surgical Oncology.
[156] K. Hemminki,et al. BRAF mutations are common somatic events in melanocytic nevi. , 2004, The Journal of investigative dermatology.
[157] R. Eeles,et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.
[158] W. Goggins,et al. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. , 2003, Archives of dermatology.
[159] Diane D. Liu,et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. , 2003, Journal of the National Cancer Institute.
[160] Matthias Rothmund,et al. CDKN2A Germline Mutations in Familial Pancreatic Cancer , 2002, Annals of surgery.
[161] J. Thiery,et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders , 2002, European Journal of Human Genetics.
[162] J. Coxhead,et al. Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[163] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[164] F. Bosman,et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. , 2002, Gastroenterology.
[165] Yubo Sun,et al. p53, proto-oncogene and rheumatoid arthritis. , 2002, Seminars in arthritis and rheumatism.
[166] Razelle Kurzrock,et al. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. , 2002, Cancer research.
[167] J. Campisi. Cellular senescence as a tumor-suppressor mechanism. , 2001, Trends in cell biology.
[168] Kathleen R. Cho,et al. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix , 2000, Oncogene.
[169] P. D. Dal Cin,et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. , 2000, The American journal of pathology.
[170] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.
[171] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[172] J. Melo,et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. , 1998, Blood.
[173] T. Rème,et al. Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue , 1998, Clinical and experimental immunology.
[174] D. Green,et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[175] A. Munnich,et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). , 1996, Human molecular genetics.
[176] G. Huez,et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. , 1995, Blood.
[177] D. Rimoin,et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.
[178] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[179] W. McGuire,et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.
[180] J U Gutterman,et al. The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.
[181] A. Ullrich,et al. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[182] R. Kurzrock,et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia , 1987, Nature.
[183] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[184] P. Dowd,et al. Atypical multiple mole melanoma syndrome. , 1979, British Journal of Dermatology.
[185] H. Lynch,et al. Familial atypical multiple mole-melanoma syndrome. , 1978, Journal of medical genetics.
[186] The Cancer Genome Atlas Research Network,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[187] Javier Munoz,et al. Molecular profiling and the reclassification of cancer: divide and conquer. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[188] S. Shvartsman,et al. RASopathies: unraveling mechanisms with animal models , 2015, Disease Models & Mechanisms.
[189] A. McCullough. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .
[190] W. High. Circulating Benign Nevus Cells Detected by ISET Technique: Warning for Melanoma Molecular Diagnosis , 2012 .
[191] D. Pinkel,et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.
[192] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[193] S. Kern,et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma–pancreatic carcinoma–prone families , 2002, Cancer.
[194] C. Grin,et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. , 1991, The Journal of dermatologic surgery and oncology.